4 results
To evaluate if treatment with only supportive care or addition of one of two anti-COVID-19 agents (chloroquine or hydroxychloroquine) results in less disease progression in patients with moderate to severe COVID-19 who require hospital admission.
The primary objective of this study is to compare the response rate of Pexidartinib with that of placebo per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) at Week 25 in subjects with symptomatic, locally advanced PVNS or GCT…
To evaluate the long-term safety and efficacy of RPC1063 for the treatment of all patients with moderate to severe UCTo evaluate the long-term efficacy of RPC1063 for the treatment of adult patients with moderate to severe UC.
Primary ObjectivesTo assess the effects of pexidartinib on the PK parameters of single-dose midazolam and tolbutamide in patients.Secondary ObjectivesTo evaluate:- To determine the overall response rate (ORR) in patients with TGCT,kit-mutant…